Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
08/19/2022 | 268.66% | HC Wainwright & Co. | $12 → $8 | Maintains | Buy |
03/29/2022 | 453% | HC Wainwright & Co. | → $12 | Initiates Coverage On | → Buy |
12/02/2021 | 245.62% | EF Hutton | → $7.5 | Initiates Coverage On | → Buy |
Nemaura Medical Questions & Answers
The latest price target for Nemaura Medical (NASDAQ: NMRD) was reported by HC Wainwright & Co. on August 19, 2022. The analyst firm set a price target for $8.00 expecting NMRD to rise to within 12 months (a possible 268.66% upside). 3 analyst firms have reported ratings in the last year.
The latest analyst rating for Nemaura Medical (NASDAQ: NMRD) was provided by HC Wainwright & Co., and Nemaura Medical maintained their buy rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Nemaura Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Nemaura Medical was filed on August 19, 2022 so you should expect the next rating to be made available sometime around August 19, 2023.
While ratings are subjective and will change, the latest Nemaura Medical (NMRD) rating was a maintained with a price target of $12.00 to $8.00. The current price Nemaura Medical (NMRD) is trading at is $2.17, which is out of the analyst's predicted range.